On June 9, the State Food and Drug Administration held a teleconference on further strengthening the quality and safety supervision of COVID-19 detection reagents, summarizing the quality and safety supervision of COVID-19 detection reagents in the previous stage, exchanging work experience, and further promoting the continuous development of COVID-19 detection in the whole system. Reagent quality and safety supervision. Xu Jinghe, member of the party group and deputy director of the State Food and Drug Administration, attended the meeting and delivered a speech.
The meeting pointed out that since the outbreak of the COVID-19, the national drug administration system has conscientiously implemented the decisions and deployments of the Party Central Committee and the State Council, fully implemented the “Regulations on the Supervision and Administration of Medical Devices”, adhered to the people’s supremacy and life first, and kept in mind that people’s health is the “bigger of the country”. Continuing to strengthen the quality and safety supervision of COVID-19 detection reagents has effectively promoted the implementation of the main responsibility of enterprises and territorial supervision responsibilities, and effectively strengthened the guarantee of product quality and safety. Recently, the first round of COVID-19 nucleic acid detection reagents in 2022 organized by the State Food and Drug Administration has fully covered the sampling inspection, and the inspection results have met the requirements.
The meeting emphasized that the quality and safety of COVID-19 detection reagents is directly related to the overall situation of epidemic prevention and control. The entire system must thoroughly implement the spirit of the instructions and instructions of the Party Central Committee and the State Council, fully implement the special rectification requirements for drug safety, further unify thinking, deepen understanding, improve political standing, and implement the “strictest supervision” on COVID-19 nucleic acid detection reagents. More resolute and powerful measures, be cautious and persistent, and continue to strengthen the quality and safety supervision of COVID-19 detection reagents. First, continue to strictly and meticulously carry out product quality supervision. The second is to continuously strengthen the quality supervision of product development. The third is to continuously strengthen the quality supervision of product production. Fourth, continue to strengthen the quality supervision of product operation links. Fifth, continue to strengthen product quality supervision in the use link. Sixth, continue to strengthen product quality supervision and sampling. Seventh, continue to severely crack down on violations of laws and regulations.
Post time: Jun-15-2022